Condition: Duchenne Muscular Dystrophy · Sponsor: Italfarmaco
This is a Phase 2 Open-label (Core Phase Plus Extension Phase) With 2 Cohorts Study to Assess the Pharmacokinetics and Safety of Givinostat in younger DMD Patients. * Planned screening duration: approximately 4 weeks * Planned Core Treatment duration: approximately 48 weeks * Planned Extension Treatment duration: approximately 96 weeks * Planned Follow Up duration: approximately 4 weeks (± 7 days) * Total duration of study participation: up to 151 weeks (ie, 37-38 months)
This description comes directly from the study's public registry record.
Italfarmaco Patient Advocacy · +39 02 64431 · patientadvocacy@italfarmacogroup.com
Italfarmaco Patient Advocacy · 0264431 · patientadvocacy@italfarmacgroup.com
Always discuss trial participation with your own doctor first.
| Queen Fabiola Children's University Hospital HUDERF | Brussels, Belgium | Recruiting |
| Fondazione Serena Onlus - Azienda Ospedaliera Niguarda Ca' Granda - NeuroMuscolar Omnicenter | Milan, Italy | Recruiting |
| Ospedale Pediatrico Bambino Gesù | Roma, Italy | Recruiting |
| Policlinico Universitario Agostino Gemelli - Università Cattolica del Sacro Cuore | Roma, Italy | Recruiting |
| Leids Universitair Medisch Centrum (LUMC) | Leiden, Netherlands | Recruiting |
| Leeds Teaching Hospital NHS Trust | Leeds, England, United Kingdom | Not Yet Recruiting |
| Great Ormond Street Hospital - GOSH | London, England, United Kingdom | Not Yet Recruiting |
| Newcastle upon Tyne Hospitals NHS Foundation Trust - Newcastle University | Newcastle upon Tyne, England, United Kingdom | Recruiting |
| Oxford University Hospitals NHS Foundation Trust | Oxford, England, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06769633